An in silico appraisal of azoic and disulphide derivatives for anticancer activity against hpv e6 oncoprotein to medicate cervical cancer

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 1, 2014, Pages 38-46

  Choudhury, Arpita Das ^a   Choudhury, Manabendra Dutta ^a   Chetia, Pankaj ^a   Chowdhury, Abhishek ^a   Talukdar, Anupam Das ^a  

^a ASSAM UNIVERSITY   (India)

Author keywords

Azoics; Cervical cancer; Disulphides; Docking; E6 oncoprotein; Human Papilloma Virus (HPVs); Pharmacophore modeling

Indexed keywords

ANTINEOPLASTIC AGENT; DISULFIDE; N (2 AMINO 2 METHYLPROPYL) N (THIOPHEN 2 YL)DIAZENE 1,2 DICARBOXAMIDE; N (2 AMINO 2 OXOETHYL) N (4 CHLOROPHENYL) DIAZENE 1,2 DICARBOXAMIDE; PROTEIN E6; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; COMPLEX FORMATION; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; FEMALE; HADEAN; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR DOCKING; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS; ZINC FINGER MOTIF;

ANTINEOPLASTIC AGENTS; AZO COMPOUNDS; COMBINATORIAL CHEMISTRY TECHNIQUES; DISULFIDES; DRUG DESIGN; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; RESEARCH DESIGN; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS; ZINC FINGERS;

EID: 84893283522     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/13862073113166660066     Document Type: Article

References (37)

1. Beaudenon, S.; Huibregtse, J. M. HPV E6, E6AP and cervical cancer. BMC Biochemistry, 2008, 9(Suppl 1), S4.
2. Pisani, P.; Parkin, D.M.; Bray, F.; Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 1999, 83, 18-29.
3. Walboomers, J.M.M.; Jacobs, M.V.; Manos, M.M.; Bosch, X.F.; Kummer, A.J.; Shah, K.V.; Snijders, P.J. F.; Peto, J.; Meijer, C.J.L.M.; Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 1999, 189, 12-19.
4. Howley, P.M. In: Fields virology; Fields, B.N.; Knipe, D.M.; Howley, P.M., Eds.; Lippincott-Raven. V: Philadelphia, 1996, Vol. 2, pp. 2045-2076.
5. International Agency for Research on Cancer (IARC), 1995, Human papillomaviruses, 64, Lyon (France): IARC.
6. Zur Hausen, H.; de Villiers, E.M. Human papillomaviruses. Annu Rev. Microbiol., 1994, 48, 427-447.
7. Wright, T.C.; Kurman, R.J. A critical review of the morphologic classification systems of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep., 1994, 5, 175-182.
8. Scheffner, M.; Huibregtse, J.M.; Howley, P.M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-APdependent ubiquitination of p53. Proc. Natl. Acad. Sci. U S A, 1994, 91, 8797-8801.
9. Sherman, L.; Jackman, A.; Itzhaki, H.; Stoppler, M. C.; Koval, D.; Schlegel, R. Inhibition of serum-and calcium-induced differentiation of human keratinocytes by HPV 16 E6 oncoprotein: role of p53 inactivation. Virology, 1997, 237, 296-306.
10. Chen, J.J.; Reid, C.E.; Band, V.; Androphy, E.J. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science, 1995, 269, 529-531.
11. Sedman, S.A.; Barbosa, M.S.; Vass, W.C.; Hubbert, N.L.; Haas, J.A.; Lowy, D.R.; Schiller, J.T. The full-length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalize keratinocytes in culture. J. Virol., 1991, 65, 4860-4866.
12. Lamberti, C.; Morrissey, L.C.; Grossman, S.R.; Androphy, E.J. Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J., 1990, 6, 1907-1913.
13. Etscheid, B.G.; Foster, S. A.; Galloway, D. A. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. Virology, 1994, 205, 583-585.
14. Klingelhutz, A.J.; Foster, S.A.; McDougall, J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature, 1996, 380, 79-82.
15. Hawley-Nelson, P.; Vousden, K.H.; Hubbert, N.L.; Lowy, D.R.; Schiller, J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J., 1989, 8, 3905-3910.
16. Myers, G.; Androphy, E.J. The E6 protein. In: Human papillomaviruses 1995
17. Meyers, G.; Bernard, H.U.; Delius, H.; Baker, C.; Icenogel, J.; Halpern, A.L.; Wheeler, C., Eds.; Los Alamos (NM): Los Alamos National Laboratory, 1995, pp. 47-57.
18. Androphy, E.J.; Hubbert, N.L.; Schiller, J.T.; Lowy, D.R. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J., 1987, 6, 989-992.
19. Grossman, S.R.; Laimins, L.A. E6 protein of human papillomavirus type 18 binds zinc. Oncogene, 1989, 4, 1089-1093.
20. Kanda, T.; Watanabe, S.; Zanma, S.; Sato, H.; Furuno, A.; Yoshike, K. Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology, 1991, 185, 536-543.
21. Beerheide, W.; Bernard, H.U.; Tan, Y.J.; Ganesan, A.; Rice, W.G.; Ting A.E. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J. Natl. Cancer Inst., 1999, 91, 1211-1220.
22. Dsouza, M.; Larsen, N.; Overbeek, R. Searching for patterns in genomic data. Trends Genet., 1997, 13, 497-498.
23. Chan, S.Y.; Delius, H.; Halpern, A.L.; Bernard, H.U. Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol., 1995, 69, 3074-3083.
24. Meyers, G. In: Human papillomaviruses 1994.
25. Meyers, G.; Bernard, H.U.; Delius, H.; Baker, C.; Icenogel, J.; Halpern, A.L.; Wheeler, C., Eds.; Los Alamos (NM): Los Alamos National Laboratory, 1994, pp. II-E6-II-E6-7.
26. Crook, T.; Tidy, J.A.; Vousden, K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell, 1991, 67, 547-556.
27. Dalal, S.; Gao, Q.; Androphy, E.J.; Band, V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol., 1996, 70, 683-688.
28. Nakagawa, S.; Watanabe, S.; Yoshikawa, H.; Taketani, Y.; Yoshiike, K.; Kanda, T. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. Virology, 1995, 212, 535-542.
29. Vousden, K. H.; Androphy, E. J.; Schiller, J. T.; Lowy, D. R. Mutational analysis of bovine papillomavirus E6 gene. J. Virol., 1989, 63, 2340-2342.
30. Nomine, Y.; Charbonnier, S.; Ristriani T.; Stier G.; Masson M.; Cavusoglu, N.; Dorsselaer, A.V.; Weiss, E.; Kieffer, B.; Trave, G. Domain substructure of HPV E6 oncoprotein: biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry, 2003, 42, 4909-4917.
31. Nomine, Y.; Masson M.; Charbonnier, S.; Zanier, K.; Ristriani T.; Deryckere, F.; Sibler, A.P.; Desplancq, D.; Atkinson, R.A.; Weiss, E.; Orfanoudakis, G.; Kieffer, B.; Trave, G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus- mediated pathogenesis. Molecular Cell, 2006, 21, 665-678.
32. Neron, B.; Menager, H.; Maufrais, C.; Joly N.; Maupetit, J.; Letort, S.; Carrere, S.; Tuffery, P.; Letondal, C. Mobyle: a new full web bioinformatics framework. Bioinformatics, 2009, 25, 3005-3011.
33. Lagorce, D.; Sperandio, O.; Galons, H.; Miteva, M.A.; Villoutreix, B.O. FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics, 2008, 9, 396.
34. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Comput. Chem., 2009, 16, 2785-2791.
35. Sanner, M.F. Python: a programming language for software integration and development. J. Mol. Graphics Mod., 1999, 17, 57-61
36. Biosolveit LeadIT. "http://www.biosolveit.de/LeadIT" (accessed 12th Mar, 2011).
37. Wolber, G.; Langer T.; Ligandscout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model, 2005, 45, 160-169.